4XV9

B-Raf Kinase domain in complex with PLX5568

4XV9 の概要

• エントリーDOI: 10.2210/pdb4xv9/pdb
• 関連するPDBエントリー: 4K04 4K16 4K1A
• 分子名称: Serine/threonine-protein kinase B-raf, N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}-4-(trifluoromethyl)benzenesulfonamide, SULFATE ION, ... (4 entities in total)
• 機能のキーワード: b-raf, braf, proto-oncogene, v600e, kinase, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• 由来する生物種: Homo sapiens (Human)
• 細胞内の位置: Nucleus : P15056
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 33907.06

構造登録者

zhang, Y.,zhang, c.,wang, w. (登録日: 2015-01-26, 公開日: 2015-10-28, 最終更新日: 2024-02-28)

主引用文献

Zhang, C.,Spevak, W.,Zhang, Y.,Burton, E.A.,Ma, Y.,Habets, G.,Zhang, J.,Lin, J.,Ewing, T.,Matusow, B.,Tsang, G.,Marimuthu, A.,Cho, H.,Wu, G.,Wang, W.,Fong, D.,Nguyen, H.,Shi, S.,Womack, P.,Nespi, M.,Shellooe, R.,Carias, H.,Powell, B.,Light, E.,Sanftner, L.,Walters, J.,Tsai, J.,West, B.L.,Visor, G.,Rezaei, H.,Lin, P.S.,Nolop, K.,Ibrahim, P.N.,Hirth, P.,Bollag, G.
RAF inhibitors that evade paradoxical MAPK pathway activation.
Nature, 526:583-586, 2015

PubMed Abstract: Oncogenic activation of BRAF fuels cancer growth by constitutively promoting RAS-independent mitogen-activated protein kinase (MAPK) pathway signalling. Accordingly, RAF inhibitors have brought substantially improved personalized treatment of metastatic melanoma. However, these targeted agents have also revealed an unexpected consequence: stimulated growth of certain cancers. Structurally diverse ATP-competitive RAF inhibitors can either inhibit or paradoxically activate the MAPK pathway, depending whether activation is by BRAF mutation or by an upstream event, such as RAS mutation or receptor tyrosine kinase activation. Here we have identified next-generation RAF inhibitors (dubbed 'paradox breakers') that suppress mutant BRAF cells without activating the MAPK pathway in cells bearing upstream activation. In cells that express the same HRAS mutation prevalent in squamous tumours from patients treated with RAF inhibitors, the first-generation RAF inhibitor vemurafenib stimulated in vitro and in vivo growth and induced expression of MAPK pathway response genes; by contrast the paradox breakers PLX7904 and PLX8394 had no effect. Paradox breakers also overcame several known mechanisms of resistance to first-generation RAF inhibitors. Dissociating MAPK pathway inhibition from paradoxical activation might yield both improved safety and more durable efficacy than first-generation RAF inhibitors, a concept currently undergoing human clinical evaluation with PLX8394.

PubMed: 26466569
DOI: 10.1038/nature14982

実験手法

X-RAY DIFFRACTION (2 Å)